About US
Contact us
-
GSK hits back at XenoPort in RLS drug disputeXenoPort knew it would get GlaxoSmithKline's ($GSK) attention with a termination notice. But the sort of attention it wanted? Probably not the sort it got.GSKhas sued the smaller company, its partner2012/2/27
-
CDC delay could temper adult uptake of Pfizer's Prevnar shotPfizer ($PFE)has pinned big hopes on Prevnar 13, the latest version of its vaccine against pneumococcus bacteria. It's already commonly used in infants and children to prevent pneumonia and meningitis2012/2/24
-
FDA adds 14 Chinese suppliers to heparin hot listFour years later, the FDA is still uncovering perps in the tainted heparin scandal. The agency said it found 14 more Chinese companies that supplied contaminated raw heparin back in 2008, when the blo2012/2/24
-
Yin Li appointed as Party Secretary and Commissioner of SFDAIn February 2012, the Central Committee of the Communist Party of China (CCCPC) and the State Council appointed Yin Li as Party Secretary and Commissioner of the State Food and Drug Administration (SF2012/2/23
-
Mexico's Genomma lodges $834M bid for PrestigeA Mexican drugmaker aims to snap up the consumer products company Prestige Brands in a deal valued at almost $850 million. Genomma Lab, based in Mexico City, offered $16.60 per share for the U.S.-base2012/2/23
-
Abbott prevails as Supremes pass on J&J patent suitThe U.S. Supreme Court won't take up the Humira patent question. The high court's decision ends an ongoing squabble over Abbott Laboratories' ($ABT) tumor necrosis factor inhibitor, and whether it ste2012/2/23
-
FDA brings Sun's Doxil copy online to fix shortageFresh off its cobbled-together solution to a methotrexate shortage, the FDA says it's sewn up an alternate supply of the scarce cancer drug Doxil. The agency has approved a substitute for the Johnso2012/2/22
-
Pfizer reportedly weighing animal health IPOPfizer isn't saying much about its divestment plans. But that doesn't stop other people from talking. The latest? An IPO for the animal-health division, reported by the Financial Times. The FT's sourc2012/2/22
-
AZ sells discounted cancer drug directly to patientsDrugmakers are getting creative about capturing sales even after their products go off patent. And AstraZeneca ($AZN)is no exception: It's launching a direct-to-patients sales program for its breast c2012/2/21
-
Jury says J&J's Risperdal didn't cause plaintiff's diabetesA New Jersey jury has let Johnson & Johnson's ($JNJ)Risperdal off the hook for a patient's diabetes. But the panel determined that the company didn't do enough to warn the man's doctor that diabet2012/2/21